

Lysando Innovations Lab GmbH

Business Strategies

Recombinant, selective acting (Artilysin®) antimicrobial proteins engineered and developed by ISO 13485 certified Lysando Innovations Lab GmbH to efficiently combat bacterial pathogens. The resulting Artilysin® platform finds application in almost all fields that are under bacterial attack.

Artilysin®

- finds particular application combating antibiotic resistant bacteria
- is effective against **gram negative** bacteria (e.g. *Acinetobacter*, *Salmonella*, *EHEC*, *Pseudomonas*)
- is effective against **gram positive** bacteria (e.g. *Staphylococcus*, *Streptococcus*)

Core Technologies and Services

Based on the Artilysin® platform, applicable Artilysin® is developed according to customer specifications. Artilysin® acts selectively so that pathogenic target bacteria are foremost eliminated and the microbiome remains intact. The bacteria are lysed via a mechanical, physical mechanism within seconds. Artilysin® is environmentally-friendly, is rapidly biologically degraded and therefore does not accumulate in the environment. Artilysin® compared to antibiotics is significantly more stable to the development of resistance.

Patent, Licenses, Co-operations

Lysando Innovations Lab GmbH distinguishes itself with goal-directed and expeditious work, is punctual and works closely with customers. Lysando Innovations Lab GmbH has much experience in working with large concerns and medium-sized companies. The Artilysin® platform is protected by a broad patent portfolio.

Distribution

Please contact our office directly: Markus Matuschka v. Greiffenclau markus@lysando.com